Natural Product (NP) Details
General Information of the NP (ID: NP4620) | |||||
---|---|---|---|---|---|
Name |
Apigenin
|
||||
Synonyms |
5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; Chamomile; Versulin; Spigenin; Apigenol; 4',5,7-Trihydroxyflavone; Apigenine; C.I. Natural Yellow 1; 5,7,4'-Trihydroxyflavone; Pelargidenon 1449; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-benzopyrone; 2-(p-Hydroxyphenyl)-5,7-dihydroxychromone; UCCF 031; NSC 83244; UNII-7V515PI7F6; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; CCRIS 3789; CHEBI:18388; CHEMBL28; EINECS 208-292-3; 4H-1-Benzopyran-4-one, 5,7-di
Click to Show/Hide
|
||||
Species Origin | Psilotum nudum ... | Click to Show/Hide | |||
Psilotum nudum | |||||
Daucus carota | |||||
Achillea millefolium | |||||
Pogostemon cablin | |||||
Chrysanthemum x morifolium | |||||
Astragalus sinicus | |||||
Juniperus chinensis | |||||
Trachelospermum jasminoides | |||||
Agrimonia pilosa | |||||
Campsis radicans | |||||
Saussurea medusa | |||||
Causonis japonica | |||||
Clerodendrum japonicum | |||||
Indigofera tinctoria | |||||
Saussurea stella | |||||
Acanthus ilicifolius | |||||
Siphonostegia chinensis | |||||
Thunbergia grandiflora | |||||
Lespedeza thunbergii | |||||
Phlomoides rotata | |||||
Clinopodium gracile | |||||
Daphne genkwa | |||||
Disease | Candidosis [ICD-11: 1F23] | Investigative | [1] | ||
Structure |
Click to Download Mol2D MOL |
||||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C15H10O5
|
||||
PubChem CID | |||||
Canonical SMILES |
C1=CC(=CC=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O
|
||||
InChI |
1S/C15H10O5/c16-9-3-1-8(2-4-9)13-7-12(19)15-11(18)5-10(17)6-14(15)20-13/h1-7,16-18H
|
||||
InChIKey |
KZNIFHPLKGYRTM-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 520-36-5
|
||||
Herb ID | |||||
ETMC ID | |||||
SymMap ID | |||||
TCMSP ID | |||||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
ABT-263 | Chronic lymphocytic leukaemia | Click to Show/Hide the Molecular Data of This Drug | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | ERK2 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | FOXO3 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | ||
HCC827 | CVCL_2063 | Lung adenocarcinoma | Homo sapiens | |||
NCI-H1650 | CVCL_1483 | Lung adenocarcinoma | Homo sapiens | |||
NCI-H3255 | CVCL_6831 | Lung adenocarcinoma | Homo sapiens | |||
SK-MEL-28 | CVCL_0526 | Cutaneous melanoma | Homo sapiens | |||
Experimental
Result(s) |
Apigenin upregulated the expression of Noxa in EGFRm tumor cells by targeting the AKT-FoxO3a pathway, thereby synergizing with ABT-263 to suppress tumor cell growth and proliferation in vitro and in vivo. | |||||
HA14-1 | Colon cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | CAPN1 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP8 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | EGFR | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
Biological
Regulation |
Up-regulation | Ratio of Bax to Bcl-2 | ||||
Up-regulation | Cytochrome c release | |||||
In-vitro Model | SK-N-DZ | CVCL_1701 | Neuroblastoma | Homo sapiens | ||
SH-SY5Y | CVCL_0019 | Neuroblastoma | Homo sapiens | |||
IMR-32 | CVCL_0346 | Neuroblastoma | Homo sapiens | |||
Experimental
Result(s) |
Bcl-2 inhibitor and apigenin worked synergistically in human malignant neuroblastoma cell lines and increased apoptosis with activation of extrinsic and intrinsic pathways. | |||||
Cetuximab | Colorectal cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [4] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | EGFR | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | STAT3 | Molecule Info |
Pathway MAP
|
||
Biological
Regulation |
Induction | Cell cycle arrest in G2/M phase | ||||
In-vitro Model | HONE-1 | CVCL_8706 | Nasopharyngeal carcinoma | Homo sapiens | ||
CNE-2 | CVCL_6889 | Human nasopharyngeal carcinoma | Homo sapiens | |||
Experimental
Result(s) |
Apigenin enhances the antitumor effects of cetuximab in nasopharyngeal carcinoma by inhibiting EGFR signaling. | |||||
Abivertinib | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [5] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | GSK-3B | Molecule Info |
Pathway MAP
|
|
In-vitro Model | U-2932 | CVCL_1896 | B-cell lymphoma | Homo sapiens | ||
OCI-Ly10 | CVCL_8795 | B-cell lymphoma | Homo sapiens | |||
Experimental
Result(s) |
Apigenin can synergize with Abivertinib in treating DLBCL visa synergistically inducing apoptosis and inhibiting the p-GS3K-beta and its downstream targets. | |||||
Gefitinib | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [6] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | BCL2L11 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | CYB5R2 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | CYM | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | HIF-1A | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | MYC | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | PRKAA1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | SLC2A1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | SLC2A3 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | SLC2A4 | Molecule Info |
Pathway MAP
|
||
Biological
Regulation |
Down-regulation | Autophagy flux | ||||
Induction | Cell cycle arrest in G0/G1 phase | |||||
In-vitro Model | NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | ||
Experimental
Result(s) |
Apigenin combined with gefitinib blocks autophagy flux and induces apoptotic cell death through inhibition of HIF-1alpha, c-Myc, p-EGFR, and glucose metabolism in EGFR L858R+T790M-mutated H1975 Cells. | |||||
TRAIL/Apo2L | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [7] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | SLC25A5 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | TRAIL-R2 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | DU145 | CVCL_0105 | Prostate carcinoma | Homo sapiens | ||
LNCaP | CVCL_0395 | Prostate carcinoma | Homo sapiens | |||
Experimental
Result(s) |
Apigenin sensitizes prostate cancer cells to Apo2L/TRAIL by targeting adenine nucleotide translocase-2. | |||||
Sorafenib | Renal cell carcinoma | Click to Show/Hide the Molecular Data of This Drug | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [8] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | BID | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | CASP10 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | CASP8 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | CDKN2A | Molecule Info |
Pathway MAP
|
||
In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
Experimental
Result(s) |
The combination of apigenin and sorafenib arrested cell cycle and increased apoptotic gene expressions more than single treatment groups. | |||||
5-fluorouracil | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [9] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
Biological
Regulation |
Up-regulation | ROS generation | ||||
Down-regulation | Loss of mitochondrial membrane potential | |||||
In-vitro Model | SK-HEP-1 | CVCL_0525 | Hepatocellular carcinoma | Homo sapiens | ||
BEL-7402 | CVCL_5492 | Human hepatocellular carcinoma | Homo sapiens | |||
In-vivo Model | SK-Hep-1 cells (5*106 cells per mice) were suspended in 100 L of serum-free RPMI-1640 medium, then subcutaneously injected into the left flank of nude mice (Male, 4-6 weeks old). | |||||
Experimental
Result(s) |
Apigenin may potentiate the cytotoxicity of 5-FU in HCC via inhibition of ROS-mediated drug resistance and concurrent activation of the mitochondrial pathways of apoptosis. | |||||
Gemcitabine | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [10] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | MIA PaCa-2 | CVCL_0428 | Pancreatic ductal adenocarcinoma | Homo sapiens | ||
AsPC-1 | CVCL_0152 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
In-vivo Model | Male BALB/c nude mice were subcutaneously inoculated with MiaPaca-2 cells (1*106 cells/mouse) cells in 1 mL of Matrigel. | |||||
Experimental
Result(s) |
The combination of gemcitabine and apigenin enhanced anti-tumor efficacy through Akt and NF-kappa B activity suppression and apoptosis induction. | |||||
TNF-related apoptosis inducing ligand | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [11] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | LNCaP | CVCL_0395 | Prostate carcinoma | Homo sapiens | ||
DU145 | CVCL_0105 | Prostate carcinoma | Homo sapiens | |||
Experimental
Result(s) |
Apigenin markedly augmented TRAIL-mediated apoptosis in prostate cancer cells . | |||||
β. A List of Drug(s) Whose Adverse Effect can be Decreased by This NP | ||||||
Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [12] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | IL19 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | IL6 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | TNF | Molecule Info |
Pathway MAP
|
||
In-vivo Model | Adult female Wistar Albino mice weighing 10-12g were used in this study. | |||||
Experimental
Result(s) |
Apigenin and myricetin exhibited a protective and promising preventive strategy against cisplatin-induced nephrotoxicity due to their antioxidant and anti-inflammatory effects. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Aldose reductase (AKR1B1) | Molecule Info | [13] | |
Androgen receptor (AR) | Molecule Info | [14] | ||
Aromatase (CYP19A1) | Molecule Info | [15] | ||
Casein kinase II alpha (CSNK2A1) | Molecule Info | [16] | ||
Cyclin-dependent kinase 6 (CDK6) | Molecule Info | [17] | ||
Cytochrome P450 1B1 (CYP1B1) | Molecule Info | [18] | ||
Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) | Molecule Info | [19] | ||
Influenza Neuraminidase (Influ NA) | Molecule Info | [20] | ||
Plasmodium CDK Pfmrk (Malaria Pfmrk) | Molecule Info | [21] | ||
BioCyc | Methylglyoxal degradation III | Click to Show/Hide | ||
2 | Acetone degradation I (to methylglyoxal) | |||
3 | Superpathway of steroid hormone biosynthesis | |||
4 | Estradiol biosynthesis II | |||
5 | Estradiol biosynthesis I | |||
6 | Superpathway of tryptophan utilization | |||
7 | Superpathway of melatonin degradation | |||
8 | Melatonin degradation I | |||
KEGG Pathway | Oocyte meiosis | Click to Show/Hide | ||
2 | Pathways in cancer | |||
3 | Prostate cancer | |||
4 | Cell cycle | |||
5 | p53 signaling pathway | |||
6 | PI3K-Akt signaling pathway | |||
7 | Hepatitis B | |||
8 | Measles | |||
9 | Viral carcinogenesis | |||
10 | MicroRNAs in cancer | |||
11 | Pancreatic cancer | |||
12 | Glioma | |||
13 | Melanoma | |||
14 | Chronic myeloid leukemia | |||
15 | Small cell lung cancer | |||
16 | Non-small cell lung cancer | |||
17 | Pentose and glucuronate interconversions | |||
18 | Fructose and mannose metabolism | |||
19 | Galactose metabolism | |||
20 | Glycerolipid metabolism | |||
21 | Metabolic pathways | |||
22 | Steroid hormone biosynthesis | |||
23 | Ovarian steroidogenesis | |||
24 | Tryptophan metabolism | |||
25 | Metabolism of xenobiotics by cytochrome P450 | |||
26 | Chemical carcinogenesis | |||
27 | Ribosome biogenesis in eukaryotes | |||
28 | NF-kappa B signaling pathway | |||
29 | Wnt signaling pathway | |||
30 | Adherens junction | |||
31 | Tight junction | |||
32 | Herpes simplex infection | |||
33 | Epstein-Barr virus infection | |||
34 | Other glycan degradation | |||
NetPath Pathway | EGFR1 Signaling Pathway | Click to Show/Hide | ||
2 | AndrogenReceptor Signaling Pathway | |||
3 | FSH Signaling Pathway | |||
4 | TGF_beta_Receptor Signaling Pathway | |||
5 | IL1 Signaling Pathway | |||
6 | TSH Signaling Pathway | |||
7 | IL4 Signaling Pathway | |||
Panther Pathway | Androgen/estrogene/progesterone biosynthesis | Click to Show/Hide | ||
Pathwhiz Pathway | Fructose and Mannose Degradation | Click to Show/Hide | ||
2 | Pyruvate Metabolism | |||
3 | Pterine Biosynthesis | |||
4 | Glycerolipid Metabolism | |||
5 | Galactose Metabolism | |||
6 | Androgen and Estrogen Metabolism | |||
Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | Click to Show/Hide | ||
2 | Coregulation of Androgen receptor activity | |||
3 | Regulation of Androgen receptor activity | |||
4 | Nongenotropic Androgen signaling | |||
5 | Regulation of nuclear beta catenin signaling and target gene transcription | |||
6 | FOXA1 transcription factor network | |||
7 | Notch-mediated HES/HEY network | |||
8 | p73 transcription factor network | |||
9 | C-MYB transcription factor network | |||
10 | IL2 signaling events mediated by STAT5 | |||
11 | Regulation of retinoblastoma protein | |||
12 | BCR signaling pathway | |||
13 | Atypical NF-kappaB pathway | |||
14 | DNA-PK pathway in nonhomologous end joining | |||
15 | Presenilin action in Notch and Wnt signaling | |||
16 | Role of Calcineurin-dependent NFAT signaling in lymphocytes | |||
17 | E-cadherin signaling in the nascent adherens junction | |||
18 | Lissencephaly gene (LIS1) in neuronal migration and development | |||
19 | PDGFR-alpha signaling pathway | |||
20 | Signaling mediated by p38-alpha and p38-beta | |||
21 | Alpha-synuclein signaling | |||
Reactome | Nuclear Receptor transcription pathway | Click to Show/Hide | ||
2 | Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | |||
3 | Oxidative Stress Induced Senescence | |||
4 | Senescence-Associated Secretory Phenotype (SASP) | |||
5 | Oncogene Induced Senescence | |||
6 | Cyclin D associated events in G1 | |||
7 | Endogenous sterols | |||
8 | Condensation of Prometaphase Chromosomes | |||
9 | The canonical retinoid cycle in rods (twilight vision) | |||
WikiPathways | SIDS Susceptibility Pathways | Click to Show/Hide | ||
2 | Integrated Pancreatic Cancer Pathway | |||
3 | Prostate Cancer | |||
4 | Integrated Breast Cancer Pathway | |||
5 | Nuclear Receptors | |||
6 | Androgen receptor signaling pathway | |||
7 | DNA Damage Response | |||
8 | G1 to S cell cycle control | |||
9 | Wnt Signaling Pathway Netpath | |||
10 | Retinoblastoma (RB) in Cancer | |||
11 | Signaling Pathways in Glioblastoma | |||
12 | Metastatic brain tumor | |||
13 | miR-targeted genes in muscle cell - TarBase | |||
14 | miR-targeted genes in lymphocytes - TarBase | |||
15 | miR-targeted genes in leukocytes - TarBase | |||
16 | miR-targeted genes in epithelium - TarBase | |||
17 | Mitotic G1-G1/S phases | |||
18 | Cell Cycle | |||
19 | miRNAs involved in DNA damage response | |||
20 | miRNA Regulation of DNA Damage Response | |||
21 | Metapathway biotransformation | |||
22 | Polyol Pathway | |||
23 | Metabolism of steroid hormones and vitamin D | |||
24 | Tryptophan metabolism | |||
25 | Oxidation by Cytochrome P450 | |||
26 | Ovarian Infertility Genes | |||
27 | FSH signaling pathway | |||
28 | Phase 1 - Functionalization of compounds | |||
29 | Estrogen metabolism | |||
30 | Benzo(a)pyrene metabolism | |||
31 | Tamoxifen metabolism | |||
32 | Nuclear Receptors Meta-Pathway | |||
33 | Estrogen Receptor Pathway | |||
34 | Sulindac Metabolic Pathway | |||
35 | Arylhydrocarbon receptor (AhR) signaling pathway | |||
36 | miR-targeted genes in adipocytes - TarBase | |||
37 | Mitotic Prometaphase | |||
38 | BDNF signaling pathway | |||
39 | TNF alpha Signaling Pathway | |||
40 | L1CAM interactions | |||
41 | Steroid Biosynthesis |